CD4-CD8- T-cells in primary Sjögren's syndrome: Association with the extent of glandular involvement

Journal of Autoimmunity

Volumn 51, Issue , 2014, Pages 38-43

  Alunno, Alessia ^a   Carubbi, Francesco ^b   Bistoni, Onelia ^a   Caterbi, Sara ^a   Bartoloni, Elena ^a   Bigerna, Barbara ^a   Pacini, Roberta ^a   Beghelli, Daniela ^c   Cipriani, Paola ^b   Giacomelli, Roberto ^b   Gerli, Roberto ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c UNIVERSITY OF CAMERINO   (Italy)

Author keywords

Double negative T cells; Minor salivary gland biopsy; Sjogren's syndrome; Th17 cells

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 17;

ADULT; ARTICLE; B LYMPHOCYTE; BLOOD; CLINICAL ARTICLE; DISEASE ASSOCIATION; DOUBLE NEGATIVE T CELL; FEMALE; FLOW CYTOMETRY; GERMINAL CENTER; HISTOLOGY; HUMAN; HUMAN CELL; MINOR SALIVA GLAND; MONONUCLEAR CELL; PRIORITY JOURNAL; SJOEGREN SYNDROME; T LYMPHOCYTE SUBPOPULATION; TH17 CELL; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; ANTIGENS, CD4; ANTIGENS, CD8; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; SALIVARY GLANDS, MINOR; SJOGREN'S SYNDROME; T-LYMPHOCYTE SUBSETS;

EID: 84901285092     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2014.01.030     Document Type: Article

References (48)

1. Mavragani C.P., Nezos A., Moutsopoulos H.M. New advances in the classification, pathogenesis and treatment of Sjogren's syndrome. Curr Opin Rheumatol 2013, 25:623-629.
2. Nocturne G., Mariette X. Advances in understanding the pathogenesis of primary Sjögren's syndrome. Nat Rev Rheumatol 2013, 9:544-556.
3. Tzioufas A.G., Kapsogeorgou E.K., Moutsopoulos H.M. Pathogenesis of Sjögren's syndrome: what we know and what we should learn. JAutoimmun 2012, 39:4-8.
4. Singh N., Cohen P.L. The T cell in Sjogren's syndrome: force majeure, not spectateur. JAutoimmun 2012, 39:229-233.
5. Ambrosi A., Espinosa A., Wahren-Herlenius M. IL-17: a new actor in IFN-driven systemic autoimmune diseases. Eur J Immunol 2012, 42:2274-2284.
6. Apostolidis S.A., Crispín J.C., Tsokos G.C. IL-17-producing T cells in lupus nephritis. Lupus 2011, 20:120-124.
7. van Hamburg J.P., Corneth O.B., Paulissen S.M., Davelaar N., Asmawidjaja P.S., Mus A.M., et al. IL-17/Th17 mediated synovial inflammation is IL-22 independent. Ann Rheum Dis 2013, 72:1700-1707.
8. Shao S., He F., Yang Y. Th17 cells in type 1 diabetes. Cell Immunol 2012, 280:16-21.
9. Nguyen C.Q., Hu M.H., Li Y., Stewart C., Peck A.B. Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjogren's syndrome. Arthritis Rheum 2008, 58:734-743.
10. Katsifis G.E., Rekka S., Moutsopoulos N.M., Pillemer S., Wahl S.M. Systemic and local interleukin-17 and linked cytokines associated with Sjögren's syndrome immunopathogenesis. Am J Pathol 2009, 175:1167-1177.
11. Moriyama M., Tanaka A., Maehara T., Furukawa S., Nakashima H., Nakamura S. Thelper subsets in Sjögren's syndrome and IgG4-related dacryoadenitis and sialoadenitis: a critical review. JAutoimmun 2014, 51:81-88.
12. Chen D.Y., Chen Y.M., Wen M.C., Hsieh T.Y., Hung W.T., Lan J.L. The potential role of Th17 cells and Th17-related cytokines in the pathogenesis of lupus nephritis. Lupus 2012, 21:1385-1396.
13. Crispín J.C., Oukka M., Bayliss G., Cohen R.A., Van Beek C.A., Stillman I.E., et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. JImmunol 2008, 181:8761-8766.
14. Alunno A., Bistoni O., Bartoloni E., Caterbi S., Bigerna B., Tabarrini A., et al. IL-17-producing CD4-CD8- T cells are expanded in the peripheral blood, infiltrate salivary glands and are resistant to corticosteroids in patients with primary Sjogren's syndrome. Ann Rheum Dis 2013, 72:286-292.
15. Wang Y., Ito S., Chino Y., Iwanami K., Yasukochi T., Goto D., et al. Use of laser microdissection in the analysis of renal-infiltrating T cells in MRL/lpr mice. Mod Rheumatol 2008, 18:385-393.
16. Zhang Z., Kyttaris V.C., Tsokos G.C. The role of IL-23/IL-17 axis in lupus nephritis. JImmunol 2009, 183:3160-3169.
17. Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H.M., Alexander E.L., Carsons S.E., et al. European Study Group on classification criteria for Sjögren's Syndrome. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002, 61:554-558.
18. Seror R., Ravaud P., Bowman S.J., Baron G., Tzioufas A., Theander E., et al. EULAR Sjögren's Task Force. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis 2010, 69:1103-1109.
19. Giusti L., Baldini C., Bazzichi L., Ciregia F., Tonazzini I., Mascia G., et al. Proteome analysis of whole saliva: a new tool for rheumatic diseases-the example of Sjögren's syndrome. Proteomics 2007, 7:1634-1643.
20. Greenspan J.S., Daniels T.E., Talal N., Sylvester R.A. The histopathology of Sjögren's syndrome in labial salivary gland biopsies. Oral Surg Oral Med Oral Pathol 1974, 37:217-229.
21. Chisholm D.M., Mason D.K. Labial salivary gland biopsy in Sjögren's disease. JClin Pathol 1968, 21:656-660.
22. Tarpley T.M., Anderson G.L., White C.L. Minor salivary gland involvement in Sjogren's syndrome. Oral Surg 1974, 37:64-74.
23. Ciccia F., Giardina A., Rizzo A., Guggino G., Cipriani P., Carubbi F., et al. Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren's syndrome. Ann Rheum Dis 2013, 72:782-783.
24. D'Acquisto F., Crompton T. CD3+CD4-CD8- (double negative) T cells: saviours or villains of the immune response?. Biochem Pharmacol 2011, 82:333-340.
25. Zlotnik A., Godfrey D.I., Fischer M., Suda T. Cytokine production by mature and immature CD4-CD8- T cells. Alpha beta-T cell receptor+ CD4-CD8- T cells produce IL-4. JImmunol 1992, 149:1211-1215.
26. Maione F., Paschalidis N., Iqbal A.J., Crompton T., Perretti M., D'Acquisto F. Analysis of the inflammatory response in HY-TCR transgenic mice highlights the pathogenic potential of CD4- CD8- T cells. Autoimmunity 2010, 43:672-681.
27. Reinhardt C., Melms A. Normalization of elevated CD4-/CD8- (double-negative) T cells after thymectomy parallels clinical remission in myasthenia gravis associated with thymic hyperplasia but not thymoma. Ann Neurol 2000, 48:603-608.
28. Bleesing J.J., Brown M.R., Dale J.K., Straus S.E., Lenardo M.J., Puck J.M., et al. TcR-alpha/beta(+) CD4(-)CD8(-) T cells in humans with the autoimmune lymphoproliferative syndrome express a novel CD45 isoform that is analogous to murine B220 and represents a marker of altered O-glycan biosynthesis. Clin Immunol 2001, 100:314-324.
29. Nalbandian A., Crispín J.C., Tsokos G.C. Interleukin-17 and systemic lupus erythematosus: current concepts. Clin Exp Immunol 2009, 157:209-215.
30. Crispin J.C., Tsokos G.C. IL-17 in systemic lupus erythematosus. JBiomed Biotechnol 2010, 2010:943254.
31. Shivakumar S., Tsokos G.C., Datta S.K. Tcell receptor alpha/beta expressing double-negative (CD4-/CD8-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. JImmunol 1989, 143:103-112.
32. Sieling P.A., Porcelli S.A., Duong B.T., Spada F., Bloom B.R., Diamond B., et al. Human double-negative T cells in systemic lupus erythematosus provide help for IgG and are restricted by CD1c. JImmunol 2000, 165:5338-5344.
33. Anand A., Dean G.S., Quereshi K., Isenberg D.A., Lydyard P.M. Characterization of CD3+ CD4- CD8- (double negative) T cells in patients with systemic lupus erythematosus: activation markers. Lupus 2002, 11:493-500.
34. Yamada H., Nakashima Y., Okazaki K., Mawatari T., Fukushi J.I., Kaibara N., et al. Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis. Ann Rheum Dis 2008, 67:1299-1304.
35. Gullick N.J., Abozaid H.S., Jayaraj D.M., Evans H.G., Scott D.L., Choy E.H., et al. Enhanced and persistent levels of IL-17+CD4+ T cells and serum IL-17 in patients with early inflammatory arthritis. Clin Exp Immunol 2013, 174(2):292-301.
36. Grishkan I.V., Ntranos A., Calabresi P.A., Gocke A.R. Helper T cells down-regulate CD4 expression upon chronic stimulation giving rise to double-negative T cells. Cell Immunol 2013, 284:68-74.
37. Christodoulou M.I., Kapsogeorgou E.K., Moutsopoulos H.M. Characteristics of the minor salivary gland infiltrates in Sjögren's syndrome. JAutoimmun 2010, 34:400-407.
38. Voulgarelis M., Tzioufas A.G. Pathogenetic mechanisms in the initiation and perpetuation of Sjögren's syndrome. Nat Rev Rheumatol 2010, 6:529-537.
39. Sakai A., Sugawara Y., Kuroishi T., Sasano T., Sugawara S. Identification of IL-18 and Th17 cells in salivary glands of patients with Sjögren's syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18. JImmunol 2008, 181:2898-2906.
40. Alunno A., Petrillo M.G., Nocentini G., Bistoni O., Bartoloni E., Caterbi S., et al. Characterization of a new regulatory CD4+ T cell subset in primary Sjogren's syndrome. Rheumatology (Oxford) 2013, 52:1387-1396.
41. Fox R.I. Sjögren's syndrome. Lancet 2005, 366:321-331.
42. Pijpe J., Kalk W.W., Bootsma H., Spijkervet F.K., Kallenberg C.G., Vissink A. Progression of salivary gland dysfunction in patients with Sjogren's syndrome. Ann Rheum Dis 2007, 66:107-112.
43. Pijpe J., Kalk W.W., van der Wal J.E., Vissink A., Kluin P.M., Roodenburg J.L., et al. Parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sjogren's syndrome. Rheumatology (Oxford) 2007, 46:335-341.
44. Seror R., Gottenberg J.E., Devauchelle-Pensec V., Dubost J.J., Le Guern V., Hayem G., et al. ESSDAI and ESSPRI: EULAR indexes for a complete picture of primary Sjögren's syndrome patients. Arthritis Care Res (Hoboken) 2013, 65:1358-1364.
45. Fox P.C., Datiles M., Atkinson J.C., Macynski A.A., Scott J., Fletcher D., et al. Prednisone and piroxicam for treatment of primary Sjögren's syndrome. Clin Exp Rheumatol 1993, 11:149-156.
46. Mavragani C.P., Moutsopoulos H.M. Conventional therapy of Sjogren's syndrome. Clin Rev Allergy Immunol 2007, 32:284-291.
47. Theander E., Vasaitis L., Baecklund E., Nordmark G., Warfvinge G., Liedholm R., et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome. Ann Rheum Dis 2011, 70:1363-1368.
48. Carubbi F., Cipriani P., Marrelli A., Di Benedetto P., Ruscitti P., Berardicurti O., et al. Efficacy and safety of Rituximab treatment in early primary Sjogren's Syndrome: a prospective, multi-center, follow-up study. Arthritis Res Ther 2013, 15:R172.